Drug Approval | February 24, 2026
FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
Patients can now get the starting 2.5 mg dose for $299 per month
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
The move signals a major expansion in access to next-generation weight-loss therapies
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
Subscribe To Our Newsletter & Stay Updated
